Almost half of people with excess weight turn to GLP-1s as a first-line treatment, leading to less sustainable outcomes and rising healthcare costs. By partnering with Vida, we are improving access to obesity specialty care and helping organizations manage costs and deliver better results. Download our newest case study to learn how you can lower…